Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Long-Term Deferred Tax (2022 - 2023)

Historic Long-Term Deferred Tax for InMed Pharmaceuticals (INM) over the last 2 years, with Q2 2023 value amounting to $21.2 million.

  • InMed Pharmaceuticals' Long-Term Deferred Tax rose 1325.53% to $21.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $21.2 million, marking a year-over-year increase of 1325.53%. This contributed to the annual value of $21.2 million for FY2023, which is 1325.53% up from last year.
  • According to the latest figures from Q2 2023, InMed Pharmaceuticals' Long-Term Deferred Tax is $21.2 million, which was up 1325.53% from $18.8 million recorded in Q2 2022.
  • InMed Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $21.2 million for Q2 2023, and its period low was $18.8 million during Q2 2022.